Literature DB >> 17159134

MRI in patients with high-grade gliomas treated with bevacizumab and chemotherapy.

Marc C Chamberlain.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 17159134     DOI： 10.1212/01.wnl.0000250628.10420.d8

Source DB:  PubMed          Journal:  Neurology        ISSN： 0028-3878            Impact factor:   9.910


× No keyword cloud information.
  10 in total

1.  Predictive imaging marker of bevacizumab efficacy: perfusion MRI.

Authors:  Whitney B Pope
Journal:  Neuro Oncol       Date:  2015-04-24       Impact factor: 12.300

Review 2.  Pros and cons of current brain tumor imaging.

Authors:  Benjamin M Ellingson; Patrick Y Wen; Martin J van den Bent; Timothy F Cloughesy
Journal:  Neuro Oncol       Date:  2014-10       Impact factor: 12.300

3.  Measuring clinical benefit: use of patient-reported outcomes (PRO) in primary brain tumor clinical trials.

Authors:  Terri S Armstrong
Journal:  Curr Oncol Rep       Date:  2013-02       Impact factor: 5.075

Review 4.  Pseudoprogression, radionecrosis, inflammation or true tumor progression? challenges associated with glioblastoma response assessment in an evolving therapeutic landscape.

Authors:  Benjamin M Ellingson; Caroline Chung; Whitney B Pope; Jerrold L Boxerman; Timothy J Kaufmann
Journal:  J Neurooncol       Date:  2017-04-05       Impact factor: 4.130

Review 5.  Anti-angiogenic therapy in glioma.

Authors:  Nicholas Butowski
Journal:  Clin Transl Oncol       Date:  2011-05       Impact factor: 3.405

6.  Low Concentration Microenvironments Enhance the Migration of Neonatal Cells of Glial Lineage.

Authors:  Richard A Able; Celestin Ngnabeuye; Cade Beck; Eric C Holland; Maribel Vazquez
Journal:  Cell Mol Bioeng       Date:  2012-06       Impact factor: 2.321

Review 7.  Response criteria for glioma.

Authors:  A Gregory Sorensen; Tracy T Batchelor; Patrick Y Wen; Wei-Ting Zhang; Rakesh K Jain
Journal:  Nat Clin Pract Oncol       Date:  2008-08-19

Review 8.  Quantitative magnetic resonance imaging biomarkers in oncological clinical trials: Current techniques and standardization challenges.

Authors:  Jie Deng; Yi Wang
Journal:  Chronic Dis Transl Med       Date:  2017-03-11

Review 9.  Modified Criteria for Radiographic Response Assessment in Glioblastoma Clinical Trials.

Authors:  Benjamin M Ellingson; Patrick Y Wen; Timothy F Cloughesy
Journal:  Neurotherapeutics       Date:  2017-04       Impact factor: 7.620

Review 10.  Response assessment criteria for glioblastoma: practical adaptation and implementation in clinical trials of antiangiogenic therapy.

Authors:  Olivier L Chinot; David R Macdonald; Lauren E Abrey; Gudrun Zahlmann; Yannick Kerloëguen; Timothy F Cloughesy
Journal:  Curr Neurol Neurosci Rep       Date:  2013-05       Impact factor: 5.081
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.